<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37218552</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.</ArticleTitle><Pagination><StartPage>1417</StartPage><EndPage>1421</EndPage><MedlinePgn>1417-1421</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14752</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Lupus nephritis (LN) is a common type of organ damage which occurs in SLE patients and is characterized by recurrent proteinuria. Activation of B lymphocytes can lead to refractory LN, which is an important pathogenic factor in SLE. B lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL) are predominantly produced by myeloid cells (monocytes, dendritic cells, neutrophils, etc) to regulate B lymphocyte function. Telitacicept was the first dual-targeting biological drug which targeted both BLyS and APRIL. Telitacicept has passed a phase II clinical trial and has since been approved for the treatment of SLE.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We report a case of SLE confirmed by renal biopsy as proliferative lupus nephritis (PLN) with massive proteinuria, which was treated with telitacicept (European League Against Rheumatism / American College of Rheumatology 2019 standard). During the 19&#x2009;months of follow-up, the patient's renal function was stable, massive proteinuria was relieved, and creatinine and blood pressure did not increase.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">During the 19&#x2009;months of telitacicept treatment (160&#x2009;mg once weekly), PLN reduced blood system damage and proteinuria without increasing the risk of infection.</AbstractText><CopyrightInformation>&#xa9; 2023 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jing-Wen</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-0814-8694</Identifier><AffiliationInfo><Affiliation>The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>Jing-Yi</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Si-Ping</ForeName><Initials>SP</Initials><Identifier Source="ORCID">0000-0003-4548-6932</Identifier><AffiliationInfo><Affiliation>The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao-Dan</ForeName><Initials>XD</Initials><AffiliationInfo><Affiliation>Guangdong Food and Drug Vocational College, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Chang-Song</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qiang</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-8510-6127</Identifier><AffiliationInfo><Affiliation>The First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Rheumatology, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000722462">telitacicept</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011507" MajorTopicYN="N">Proteinuria</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000095223" MajorTopicYN="N">White</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APRIL</Keyword><Keyword MajorTopicYN="N">B-cell lymphocyte stimulator</Keyword><Keyword MajorTopicYN="N">proliferative lupus nephritis</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">telitacicept</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>23</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37218552</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14752</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis. 2011;70(Suppl 1):i64-i66. doi:10.1136/ard.2010.142208</Citation></Reference><Reference><Citation>Yokoyama H, Wada T, Furuichi K. Chemokines in renal fibrosis. Contrib Nephrol. 2003;139:66-89. doi:10.1136/ard.2010.142208</Citation></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Working Group. KDIGO 2021 clinical practice guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021</Citation></Reference><Reference><Citation>Pons-Estel GJ, Serrano R, Plasin MA, Espinosa G, Cervera R. Epidemiology and management of refractory lupus nephritis. Autoimmun Rev. 2011;10(11):655-663. doi:10.1016/j.autrev.2011.04.032</Citation></Reference><Reference><Citation>Das U, Patel R, Guditi S, Taduri G. Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis. Lupus. 2021;30(6):876-883. doi:10.1177/0961203321995251</Citation></Reference><Reference><Citation>Stohl W. Systemic lupus erythematosus and its ABCs (APRIL/BLyS complexes). Arthritis Res Ther. 2010;12(2):111. doi:10.1186/ar2976</Citation></Reference><Reference><Citation>Mathias LM, Stohl W. Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opin Ther Targets. 2020;24(12):1283-1302. doi:10.1080/14728222.2020.1832464</Citation></Reference><Reference><Citation>Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013;22(1):63-72. doi:10.1080/14728222.2020.1832464</Citation></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. A phase III, randomised, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-3930. doi:10.1002/art.30613</Citation></Reference><Reference><Citation>Rovin BH, Furie R, Teng Y, et al. A secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. doi:10.1016/j.kint.2021.08.027</Citation></Reference><Reference><Citation>Dhillon S. Telitacicept: first approval. Drugs. 2021;81(14):1671-1675. doi:10.1016/j.kint.2021.08.027</Citation></Reference><Reference><Citation>Sun L, Shen Q, Gong Y, et al. Safety and efficacy of telitacicept in refractory childhood-onset systemic lupus erythematosus: a self-controlled before-after trial. Lupus. 2022;31(8):998-1006. doi:10.1177/09612033221097812</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>